Bart Barlogie, MD, PhD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences Little Rock, Arkansas

Elias J. Anaissie, MD
Myeloma Institute for Research and Therapy
The University of Arkansas for Medical Sciences Little Rock, Arkansas

Brian G.M. Durie, MD
Cedars-Sinai Comprehensive
Cancer Center
Los Angeles, California

Elias J. Anaissie, MD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Bart Barlogie, MD, PhD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

William I. Bensinger, MD
Fred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington

Peter Leif Bergsagel, MD
Mayo Clinic
Scottsdale, Arizona

Arthur R. Bradwell, MD
University of Birmingham
Birmingham, United Kingdom

Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Madhav V. Dhodapkar, MD
The Rockefeller University
New York, New York

Brian G.M. Durie, MD
Cedars-Sinai Comprehensive Cancer Center
Los Angeles, California

Joshua Epstein, DSc
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Michele Fox, MD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Philip R. Greipp, MD
Mayo Clinic
Rochester, Minnesota

Mohamad Hussein, MD
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Norman Latov, MD, PhD
Weill Medical College Of Cornell University
New York, New York

Nikhil Munshi, MD
Harvard Medical School
Boston, Massachusetts

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

David G. Roodman, MD, PhD
University of Pittsburgh
Pittsburgh, Pennsylvania

John D. Shaughnessy, Jr., PhD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Steven P. Treon, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Guido Tricot, MD, PhD
Myeloma Institute for Research and Therapy
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Frits Van Rhee, MD, PhD
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Ivan Van Riet, MD
Academic Hospital
Free University Brussels
Brussels, Belgium

Ronald C. Walker, MD
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Donna M. Weber, MD
MD Anderson Cancer Center
Houston, Texas

Qing Yi, MD, PhD
MD Anderson Cancer Center
Houston, Texas

Maurizio Zangari, MD
The University of Arkansas
for Medical Sciences
Little Rock, Arkansas

Friday, January 21, 2005

Session I: Pathogenesis of myeloma

Session II: Diagnosis, staging, and monitoring response of myeloma

Preventing thrombosis: Point-counterpoint
Point: Low-molecular weight heparin is key to prevention
Maurizio Zangari, MD

Counterpoint: Aspirin is all you need
Mohamad Hussein, MD

Allogeneic transplantation for high risk myeloma: Point-counterpoint
Point: Reduced intensity conditioning is safe and effective therapy
Speaker Invited

Counterpoint: Time to revisit conventional myeloablative conditioning
William I. Bensinger, MD

Imedex^®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc. designates this educational activity for a maximum of 14.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

This educational program is intended for hematologists/oncologists and other health care providers who are involved in and/or interested in multiple myeloma or plasma cell disorders. No specific knowledge or skills other than a basic training or familiarity with the practice of hematology/oncology is required for successful participation in this program.

Click here to register for this program

After successful completion of this program participants should be able to:

• Describe current treatment options for patients with multiple myeloma and other plasma cell disorders
• Comment on supportive therapies for patients with myeloma
• Comment on the prognostic value of cytogenetic markers
• Discuss immunomodulatory therapies in the treatment of multiple myeloma
• Evaluate promising new therapeutic strategies for the treatment of multiple myeloma
• Summarize the key features of the biology of multiple myeloma and other plasma cell disorders

Participants interested in presenting data should submit abstracts online by December 3, 2004. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final program book and scheduled for a poster presentation.

Acceptance notifications and guidelines for poster presentation will be sent on December 17, 2004. Authors of accepted abstracts who have not registered will have until January 14, 2005 to do so at the discounted rate. After this date, abstracts without registered presenters will be disregarded.

Submission Deadline:
December 3, 2004

Submission Instructions:
Go to www.imedex.com and click “submit an abstract”

• Follow the online instructions
• Abstracts must be written in English
• Accepted format: Word documents, 9 point Arial font, 500 word count limit
• Use a concise title
• List affiliations of author(s) as briefly as possible, with city, state and country
• Use standard and well-accepted abbreviations
• When using references, use standard and well-accepted formats
• Abstract content should be single-spaced, typed in lower case and contain:
  • Purpose of the study
  • Summarized description of the project
  • Results and conclusions

Click here to register for this program

Registration Fees
Discounted . . . . . . . . . $ 195 (If received by December 10, 2004)
Regular . . . . . . . . . . . .$ 295 (If received by January 14, 2005)
Full . . . . . . . . . . . . . . .$ 395 (If received after January 14, 2005)

Group Discount . . . . . . .– $ 50 (Physician registrants only)
Nurses, Fellows , Students* . . . $ 99 (*proof of eligibility must accompany registration)

To Register: You may register online at www.imedex.com or call Imedex at +1 (770) 751 7332 or return the registration form in this program by mail or fax. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Registration Fee Inclusions: Registration fees include admittance to scientific sessions, conference materials and all functions as specified in the program.

Group Discounts: Multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts do not apply to nurses, fellows and students.

Payment: Registration fees and hotel reservation guarantees can be remitted by credit card, check or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to the registration fee to cover bank charges. Include the full name of the attendee and the name of the conference: 210 Plasma Cell. Attendee is not registered until full payment is received.

Wire to: Bank of America, Atlanta, GA, ABA: 0260-0959-3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex by January 14, 2005. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. Attendees registered at the Nurses, Fellows and Students rate will not receive a refund. After January 14, 2005, no refunds will be made.

For hotel deposits to be refunded, written notice of cancellation must be received at Imedex no later than 5 business days prior to your scheduled arrival date. All refunds will be processed after the conference.

The Westin Casuarina
160 East Flamingo Rd.
Las Vegas, Nevada 89109
Tel.: +1 (702) 836 9775
Fax: +1 (702) 836 9776

For the convenience of attendees, a limited number of rooms has been reserved at a rate of $179.00 for single or double occupancy, plus tax, currently at 9%. This rate is not guaranteed outside the conference dates.

The Westin Casuarina is conveniently located just steps away from the famous Las Vegas "Strip", three miles from the McCarran Airport and one mile from the Las Vegas Convention Center.

          70 Technology Drive
          Alpharetta, GA 30005-3969 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com